Lee's Pharma gains rights to Solasia's Sancuso in China
Privately-held Japanese firm Solasia Pharma has entered into an exclusive license agreement with Hong Kong-based Lee’s Pharmaceutical (SEHK: 0950) for the commercialization and promotion of Sancuso (granisetron transdermal delivery system) in the People’s Republic of China, excluding Taiwan, Hong Kong, Macau and the Retained Territory.
Solasia will retain rights to promote Sancuso in three major cities (Beijing, Shanghai and Guangzhou; the “Retained Territory”) in the PRC. Under the terms of the deal, Solasia granted Lee’s Pharma an exclusive license and right for promoting, commercializing, distributing and selling Sancuso in the licensed territory for the patients suffering from chemotherapy-induced nausea vomiting (CINV) caused by chemotherapy.
Solasia obtained an exclusive license to develop and commercialize Sancuso for Asian territories from ProStrakan, a subsidiary of Japan’s Kyowa Hakko Kirin (TYO: 4151), and is currently waiting for approval from the China Food and Drug Administration.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze